Fulcrum Therapeutics (FULC) insider trading in the last 6 months

One insider bought $1.5M, 1 sold $66K.

Quality Score-2Poor

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

See all 7 tradesSee it live, free until Thursday morning. No account. No card. Then keep going with a free account.

Form 4 filings, newest first

BuyKevin Tang$415K10% ownerat $3.56 on Jul 16, filed Jul 20

BuyKevin Tang10% owner$415Kat $3.56 on Jul 16, filed Jul 20

BuyKevin Tang$179K10% ownerat $3.52 on Jul 17, filed Jul 20

BuyKevin Tang10% owner$179Kat $3.52 on Jul 17, filed Jul 20

BuyKevin Tang$382K10% ownerat $3.56 on Jul 15, filed Jul 15

BuyKevin Tang10% owner$382Kat $3.56 on Jul 15, filed Jul 15

From SEC Form 4s, the newest filed Jul 20, 2026 · Insiders have 2 business days to file a trade

4 more filings on FULC in the last 6 months, for Pro members. See them free →

Pro members see every filing on FULC with what each insider bought or sold and at what price, and can turn on an optional alert when an insider buys.

Who files at Fulcrum Therapeutics

Alan EzekowitzDirector · 1 sale

Insider trades by person

Tested. Our top-scored stocks returned 2.2x the average stock over the next month. Reconstructed after the fact; recorded live since Sep 9, 2026. How we tested it

Questions about FULC's insider trades

As of Nov 10, 2026: Fulcrum Therapeutics (FULC) has 7 insider filings on record in the last 6 months, the newest filed Jul 20, 2026. Its Quality Score is -2 (Poor). Scores as of 10:56 PM ET, 15 minutes behind.

Are FULC insiders buying or selling?

One insider bought $1.5M across 6 filings, and one insider sold $66K across 1 filing, in the last 6 months. The newest filing: Kevin Tang, 10% owner, bought $415K on Jul 16, 2026.

Who are FULC's biggest insider sellers?

The one insider who sold FULC in the last 6 months: Alan Ezekowitz (Director), 1 sale.

When did an FULC insider last buy?

Kevin Tang, 10% owner, bought FULC shares ($415K) on Jul 16, 2026, filed Jul 20, 2026, the newest insider buy on record.

Fulcrum Therapeutics's page has its Quality Score, its chart, and its earnings. More in Healthcare and Biotech.

Fulcrum Therapeutics (FULC) insider trading in the last 6 months

Form 4 filings, newest first

Who files at Fulcrum Therapeutics

Questions about FULC's insider trades

Every insider trade, with its stock's score.